In the experimental arm, participants are randomized to receive the study drug ... for the modulation of chronically inflamed ...

The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox ...

The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox ...

A 39-year-old father is suffering from a horrifically painful skin disease that doctors can't cure or even definitively ...

The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox ...

Ryan Becker from Spokane is battling a rare medical condition that has left doctors at the Mayo Clinic and Johns Hopkins ...

ORLANDO -- More than 40% of patients with longstanding prurigo nodularis (PN) had significant improvement within 3 months of ...

NIH-sponsored trial data offers further evidence to help inform mpox treatment decisions.

VentureMed Group, Inc., a medical device company focused on arteriovenous access and peripheral arterial disease, recently ...

Although the tilsotolimod plus ipilimumab treatment did not meet its co-primary endpoint, these results are a valuable addition to the literature with respect to second-line treatment options in this ...

ACTG, a global clinical trials network focused on HIV and other infectious diseases, recently presented data demonstrating ...